Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025
Immix Biopharma (NASDAQ: IMMX) announced that interim Phase 1/2 results from its U.S. NXC-201 NEXICART-2 trial in relapsed/refractory AL amyloidosis were selected for an oral presentation at ASH 2025.
The oral presentation is scheduled for December 7, 2025, 5:45–6:00 PM ET (Abstract abs25-14730) in Session 652: MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias. The presentation covers first 20-patient safety and efficacy data from NEXICART-2, described as the first U.S. CAR-T trial in relapsed/refractory light-chain (AL) amyloidosis. Event details are available on Immix Biopharma’s investor presentations page.
Immix Biopharma (NASDAQ: IMMX) ha annunciato che i risultati provvisori di fase 1/2 dal suo test statunitense NXC-201 NEXICART-2 in amiloidosi AL ricorrente/refrattaria sono stati selezionati per una presentazione orale all'ASH 2025.
La presentazione orale è prevista per 7 dicembre 2025, 17:45–18:00 ET (Abstract abs25-14730) nella Sessione 652: MGUS, Amiloidosi e altre disordini plasmocellulari non mielomici. La presentazione copre i primi dati di sicurezza ed efficacia su 20 pazienti del NEXICART-2, descritti come il primo trial CAR-T negli Stati Uniti in amiloidosi AL ricorrente/refrattaria. I dettagli dell'evento sono disponibili sulla pagina delle presentazioni agli investitori di Immix Biopharma.
Immix Biopharma (NASDAQ: IMMX) anunció que los resultados interinos de Fase 1/2 de su ensayo estadounidense NXC-201 NEXICART-2 en amiloidosis AL recaída/refractaria fueron seleccionados para una presentación oral en ASH 2025.
La presentación oral está programada para 7 de diciembre de 2025, 5:45–6:00 PM ET (Abstract abs25-14730) en la Sesión 652: MGUS, Amiloidosis y otras displasias de células plasmáticas no mielomales. La presentación cubre los primeros datos de seguridad y eficacia de 20 pacientes del NEXICART-2, descrito como el primer ensayo CAR-T en EE. UU. en amiloidosis AL de recurrencia/refractaria. Los detalles del evento están disponibles en la página de presentaciones para inversores de Immix Biopharma.
Immix Biopharma (NASDAQ: IMMX)는 미국 NXC-201 NEXICART-2 시험의 중간 Phase 1/2 결과가 재발/불응 AL 아밀로이드증에서 ASH 2025의 구두 발표로 선정되었다고 발표했습니다.
구두 발표는 2025년 12월 7일, 5:45–6:00 PM ET (초록 abs25-14730) 세션 652: MGUS, Amyloidosis 및 기타 비다발성 플라스마세포 이상에서 예정되어 있습니다. 이 발표는 재발/불응 경량사슬(AL) 아밀로이드증에서 미국 최초의 CAR-T 시험으로 설명되는 NEXICART-2의 처음 20명의 환자 안전성 및 유효성 데이터를 다룹니다. 행사 세부 정보는 Immix Biopharma의 투자자 발표 페이지에서 확인할 수 있습니다.
Immix Biopharma (NASDAQ: IMMX) a annoncé que les résultats intérimaires de phase 1/2 de son essai américain NXC-201 NEXICART-2 chez les patients atteints d'amyloïdose AL en rechute/réfractory ont été sélectionnés pour une présentation orale à l'ASH 2025.
La présentation orale est prévue pour le 7 décembre 2025, 17:45–18:00 ET (Abstract abs25-14730) dans la Session 652: MGUS, Amyloïdose et autres dyscrasies plasmocytaires non myélomiques. La présentation couvre les premiers résultats de sécurité et d’efficacité pour 20 patients issus de NEXICART-2, décrite comme le premier essai CAR-T aux États-Unis chez l’amyloïdose AL en rechute/réfractory. Les détails de l’événement sont disponibles sur la page des présentations aux investisseurs d’Immix Biopharma.
Immix Biopharma (NASDAQ: IMMX) kündigte an, dass die vorläufigen Phase-1/2-Ergebnisse ihres US-amerikanischen NXC-201 NEXICART-2-Studienprogramms bei rezidivierender/refraktärer AL-Amyloidose ausgewählt wurden, um eine orale Präsentation auf der ASH 2025 zu geben.
Die mündliche Präsentation ist für 7. Dezember 2025, 17:45–18:00 Uhr ET vorgesehen (Abstract abs25-14730) in der Session 652: MGUS, Amyloidose und andere non‑Myelom-Plasmazellerkrankungen. Die Präsentation deckt die ersten 20 Patienten-Sicherheits- und Wirksamkeitsdaten aus NEXICART-2 ab, beschrieben als der erste US-amerikanische CAR-T‑Trial bei rezidivierender/refraktärer AL-Amyloidose. Details zur Veranstaltung finden Sie auf der Investorenseite von Immix Biopharma.
Immix Biopharma (NASDAQ: IMMX) أعلنت أن نتائج المرحلة الانتقالية 1/2 من تجربتها الأمريكية NXC-201 NEXICART-2 في داء الأميلويد AL المرتجع/المقاوم قد تم اختيارها لعرض شفهي في ASH 2025.
سيُعقد العرض الشفهي في 7 ديسمبر 2025، 5:45–6:00 مساءً بالتوقيت الشرقي (Abstract abs25-14730) في الجلسة 652: MGUS، داء الأميلويد، واضطرابات البلازما الأخرى غير المتعددة النخاع. يغطي العرض البيانات الأولية للسلامة والفعالية لـ20 مريضًا من NEXICART-2، موصوف بأنه أول تجربة CAR-T في الولايات المتحدة في داء AL الأميلويد المرتجع/المقاوم. تتوفر تفاصيل الحدث على صفحة عروض المستثمرين لشركة Immix Biopharma.
- None.
- None.
- Oral presentation Sunday, December 7, at ASH 2025 -
LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that Phase 1/2 interim results from its U.S. NXC-201 NEXICART-2 trial in relapsed/refractory AL Amyloidosis has been selected for oral presentation at the upcoming American Society of Hematology 2025 Annual Meeting (ASH 2025) being held in Orlando, Florida, December 6–9, 2025.
ASH 2025 Presentation Details – NXC-201
| Title | “First 20-patient safety and efficacy data from NEXICART-2, the first U.S. trial of CAR-T in R/R light chain (AL) amyloidosis, NXC-201” |
| Presentation Date/Time (Eastern Time) |
|
Event details are available on the Immix website in the Presentation & Events section at https://immixbio.com/investors/#investor-presentation .
About AL Amyloidosis
AL amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead continuously produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death.
The number of patients in the U.S. with relapsed/refractory AL Amyloidosis is estimated to be growing at
The Amyloidosis market was
About NXC-201
NXC-201 is a sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy with a “digital filter” that filters out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the FDA, and Orphan Drug Designation (ODD) by the US FDA and in the EU by the EMA.
About NEXICART-2
NEXICART-2 (NCT06097832) is an ongoing multi-site U.S. Phase 1/2 clinical trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory AL Amyloidosis, with a registrational design. Interim results were presented at ASCO 2025 in an oral presentation. NEXICART-2 is expected to enroll 40 patients.
About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is the global leader in relapsed/refractory AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a “digital filter” that filters out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a registrational design. NXC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA. Learn more at www.immixbio.com and www.BeProactiveInAL.com.
Forward Looking Statements
This press release contains forward-looking statements regarding Immix Biopharma, Inc., its results of operations, prospects, future business plans and operations and the matters discussed above, including, but not limited to, the potential benefits of our product candidate CAR-T NXC-201 and the timing and results related to clinical trials. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Forward-looking statements also include, but are not limited to, our plans, objectives, expectations and intentions and other statements that contain words such as “expects”, “contemplates”, “anticipates”, “plans”, “intends”, “believes”, “estimates”, “potential”, and variations of such words or similar expressions that convey the uncertainty of future events or outcomes, or that do not relate to historical matters. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the further data from the ongoing Phase 1/2 clinical trials for CAR-T NXC-201 will not be favorably consistent with the data readouts to date, (ii) the risk that the Company may not be able to continue the NEXICART-2 multi-site U.S. Phase 1/2 clinical trial; (iii) the risk that the Company may not be able to advance to registration-enabling studies for CAR-T NXC-201 or other product candidates, (iv) that success in early phases of pre-clinical and clinicals trials do not ensure later clinical trials will be successful; (v) that no drug product developed by the Company has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (vi) the risk that the Company may not be able to obtain additional working capital with which to continue the clinical trials for CAR-T NXC-201, or advance to the initiation of registration-enabling studies, for such product candidates as and when needed and (vii) those other risks disclosed in the section “Risk Factors” included in the Company’s Annual Report on Form 10-K filed with the SEC on March 25, 2025 and other periodic reports subsequently filed with the Securities and Exchange Commission. These reports are available at www.sec.gov. Immix Biopharma cautions that the foregoing list of important factors is not complete. Immix Biopharma cautions readers not to place undue reliance on any forward-looking statements. Immix Biopharma does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
Contacts
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com
Company Contact
irteam@immixbio.com
FAQ
What will Immix Biopharma (IMMX) present at ASH 2025 on December 7, 2025?
When and where is the IMMX NEXICART-2 oral presentation at ASH 2025?
What specific data does the IMMX ASH 2025 talk cover for NXC-201 (NEXICART-2)?
How can investors access the Immix Biopharma NEXICART-2 ASH 2025 presentation details?
What is the ASH 2025 session for the IMMX presentation about?
Is the IMMX presentation at ASH 2025 an oral or poster session and what is the abstract number?
